261 related articles for article (PubMed ID: 28479604)
1. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy.
Kang XJ; Wang HY; Peng HG; Chen BF; Zhang WY; Wu AH; Xu Q; Huang YZ
Acta Pharmacol Sin; 2017 Jun; 38(6):885-896. PubMed ID: 28479604
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
3. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
[TBL] [Abstract][Full Text] [Related]
4. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance.
Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J
J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857
[TBL] [Abstract][Full Text] [Related]
5. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells.
Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q
Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952
[TBL] [Abstract][Full Text] [Related]
6. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug.
Ling L; Ismail M; Du Y; Yao C; Li X
Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133
[TBL] [Abstract][Full Text] [Related]
7. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect.
Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J
J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044
[TBL] [Abstract][Full Text] [Related]
8. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
10. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
[TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
13. The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
Wang C; Wang X; Zhong T; Zhao Y; Zhang WQ; Ren W; Huang D; Zhang S; Guo Y; Yao X; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2015; 10():2229-48. PubMed ID: 25834435
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-alginate BSA-gel-capsules for local chemotherapy against drug-resistant breast cancer.
Shen H; Li F; Wang D; Yang Z; Yao C; Ye Y; Wang X
Drug Des Devel Ther; 2018; 12():921-934. PubMed ID: 29719378
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells.
Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X
Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844
[TBL] [Abstract][Full Text] [Related]
17. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
[TBL] [Abstract][Full Text] [Related]
18. Endosomal escape by photo-activated fusion of liposomes containing a malachite green derivative: a novel class of photoresponsive liposomes for drug delivery vehicles.
Hayashi K; Watanabe M; Iwasaki T; Shudou M; Uda RM
Photochem Photobiol Sci; 2019 Jun; 18(6):1471-1478. PubMed ID: 30964475
[TBL] [Abstract][Full Text] [Related]
19. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
[TBL] [Abstract][Full Text] [Related]
20. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line.
Shaik MS; Chatterjee A; Singh M
J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
